In this article
Determinants of Tumor Immunity and Heterogeneity
A research team from the Abramson Cancer Center (ACC) at the University of Pennsylvania School of Medicine found that whether a tumor is hot or cold is determined by information embedded in the cancer cells themselves. “Hot” tumors are often considered more sensitive to immunotherapy. In a new study published this week in Immunity, the researchers explored the role of “tumor heterogeneity”, namely the ability of tumor cells to move, replicate, metastasize and respond to treatment. These new findings can help oncologists more accurately tailor the unique tumor composition of patients.
Ben Stanger, a professor of gastroenterology and cell and developmental biology at the University of Pennsylvania Perelman School of Medicine, said that the degree to which T cells are attracted to tumors is regulated by the tumor-specific genes. In order for tumors to grow, they need to avoid attacks by the immune system. There are two ways: to develop into cold tumors, or hot tumors that can deplete T cells, effectively protecting tumor cells from damage to the patient’s immune system.
Role of CXCL1 in Immunotherapy Resistance
In this study, researchers found that whether a tumor is hot or cold determines whether it will respond to immunotherapy. Cold tumor cells produce a compound called CXCL1, which can instruct bone marrow cells to enter the tumor, keep T cells away from the tumor, and ultimately make the immunotherapy insensitive. In contrast, knocking out CXCL1 in cold tumors promotes T cell infiltration and sensitivity to immunotherapy.
The team generated a series of cell lines that mimic the characteristics of pancreatic tumors, including the types of immune cells they contain. In the future, these tumor cell lines can help further identify and optimize treatment for specific subtypes of patients with various tumor heterogeneity states.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.